Home › NDC Lookup › Ingredients › Glipizide › 60505-0141-00
⚪image loading
(from DailyMed)

Glipizide 5 mg Tablet, 100-count — NDC 60505-0141-0 (Billing 60505-0141-00)

by Apotex Corp. · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Glipizide 5 mg Tablet from Apotex Corp., marketed since Sep 2002 and currently FDA-listed; retail pharmacies pay about $0.0339 per tablet (NADAC).

NDC 60505-0141-00
🏷️ FDA NDC (as labeled) 60505-0141-0 billing pads the package segment with a zero
This package
Contains100-count Cost per ea$0.0339 NADAC Per package$3.39 / 100 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.1223/unit · Part D plans $0.0806/unit — full pricing hub ↓
Product page 60505-0141-01 Also comes in: 500 tablets 60505-0141-2 1000 tablets 60505-0141-1 18000 tablets 60505-0141-8
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 60505-0141-0 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
60505 labeler · 0141 product · 0 package
Package marketed since
Sep 25, 2002
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 6050501410 1
Medicaid fills, this package
33,862 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 60505-0141-0
Product NDC 60505-0141
11-digit billing NDC 60505014100
NCPDP billing unit EA — each (per item)
Application # ANDA075795
SPL Set ID bac5c69c-3714-aa20-b889-dad244e07b9e
Established class (EPC) Sulfonylurea
Chemical class Sulfonylurea Compounds
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2002-09-25
Route ORAL
Dosage form TABLET
Substance GLIPIZIDE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 001777
GCN 10840
HICL code 000803
Ingredient (HICL) Glipizide
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C4
Therapeutic class — intermediate (HIC2) Antihyperglycemics
HIC3 code C4K
Therapeutic class — specific (HIC3) Antihyperglycemic, Insulin-Release Stimulant Type
AHFS code 68:20.20.00
AHFS class Sulfonylureas
FDB label name GLIPIZIDE 5 MG TABLET
FDB brand name Glipizide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001777
  • GCN: 10840
  • HICL (First Databank): 000803
  • AHFS class code: 68:20.20.00
Why two NDCs? The FDA registers this code as 60505-0141-0 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 60505-0141-00. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name GLIPIZIDE 5 MG TABLET Ingredient Glipizide
📖 What it is MedlinePlus · NLM

Glipizide is used along with diet and exercise, and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). Glipizide is in a class of medications called sulfonylureas. Glipizide lowers blood sugar by causing the pancreas to produce insulin (a natural substance that is needed to break down sugar in the body) and helping the body use insulin efficiently. This medication will only help lower blood sugar in people whose bodies produce insulin naturally. Glipizide is not...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Glipizide helps lower your blood sugar by prompting your pancreas to release more insulin — especially after meals. It's used in type 2 diabetes alongside diet and exercise, not as...
  • What exactly is glipizide supposed to do for my diabetes?
  • The regular tablet works relatively quickly and is usually taken about 30 minutes before a meal. The extended-release tablet (including the brand Glucotrol XL) releases the medicin...
  • What's the difference between the regular tablet and the extended-release tablet?
📖 Read our full Glipizide guide →
1
Nutrient depletion considerations

Glipizide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Glipizide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.034 $3.39 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1223 $12.23 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.0806 $8.06 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.037 $0.034
▼ Down 8% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
60505-0141-00 You're viewing this 100 TABLET in 1 BOTTLE $0.0339 / ea $3.39 2002-09-25 — Active
60505-0141-01 60505-0141-1 Main listing 1000 TABLET in 1 BOTTLE $0.0339 / ea $33.88 2002-09-25 — Active
60505-0141-02 60505-0141-2 500 TABLET in 1 BOTTLE $0.0339 / ea $16.94 2002-09-25 — Active
60505-0141-08 60505-0141-8 18000 TABLET in 1 BOTTLE $0.0339 / ea $609.84 2002-09-25 — Active

You're viewing the smallest of 4 pack sizes for this product.

This pack has the lowest per-ea cost of the 4 priced pack sizes ($0.0339 NADAC).

This pack accounts for about 15% of this product's recent Medicaid fills; most go to the 1000 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 60505-0141-02?
Both are Glipizide 5 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 60505-0141-02 is the 500 tablets package.
What NDC number is used to bill for this package of Glipizide 5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Glipizide 5 mg 00591-0460-01 Actavis 100 tablets $0.034 — Availability likely —
Glipizide 5 mg 00904-6637-61 Major 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 50268-0361-15 AvPAK 50 tablets $0.034 AB Availability likely —
Glipizide 5 mgthis 60505-0141-00 Apotex 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 60687-0690-01 American 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 62559-0315-10 ANI 1000 tablets $0.034 AB Availability likely —
Glipizide 5 mg 68645-0574-54 Legacy 30 tablets $0.034 AB Availability likely —
Glipizide 5 mg 69584-0309-10 Oxford 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 72888-0116-00 Advagen 1000 tablets $0.034 AB Availability likely —
Glipizide 5 mg 00615-8407-05 NCS 15 tablets — AB FDA listed —
Glipizide 5 mg 43353-0207-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 50090-0502-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6473-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6975-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 50090-7755-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-7756-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 50090-7908-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 51407-0620-10 Golden 1000 tablets — AB FDA listed —
Glipizide 5 mg 51655-0180-25 Northwind 60 tablets — AB FDA listed —
Glipizide 5 mg 55154-7987-00 Cardinal 10 tablets — AB FDA listed —
Glipizide 5 mg 55289-0806-93 PD-Rx 180 tablets — AB FDA listed —
Glipizide 5 mg 63629-1398-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 67046-0236-03 Coupler 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-3548-06 NuCare 60 tablets — AB FDA listed —
Glipizide 5 mg 68071-4085-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-4223-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-4857-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 68071-4939-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-0141-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-4020-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-8512-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 70518-0552-00 REMEDYREPACK 30 tablets — AB FDA listed —
Glipizide 5 mg 71205-0041-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 71335-0930-01 Bryant 100 tablets — AB Discontinued —
Glipizide 5 mg 71335-2520-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-2528-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-3133-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71610-0175-60 Aphena 90 tablets — AB FDA listed —
Glipizide 5 mg 71610-0680-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 72162-2103-00 Bryant 1000 tablets — AB FDA listed —
Glipizide 5 mg 72789-0130-30 PD-Rx 30 tablets — AB FDA listed —
Glipizide 5 mg 72789-0464-86 PD-Rx 360 tablets — AB FDA listed —
Glipizide 5 mg 82804-0174-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 82804-0959-00 Proficient 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-4178-01 Preferred 100 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2002
On the market since
Sep 2002
📍
2026
Currently FDA-listed
24 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Glipizide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerApotex Corp.
Application holderAPOTEX INC
FDA applicationANDA075795 (ANDA)
Labeler code60505
First marketedSep 2002
Product typeHuman Prescription Drug
Portfolio313 products on file

More NDCs from Apotex Corp. labeler code 60505

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
33.9K
Units reimbursed last 4 qtrs
2.8M
Gross reimbursed last 4 qtrs
$346K
Avg / prescription
$10.22
Avg / unit
$0.1223
Latest quarter Q1 2026
7.2KRx
Medicaid pays / ea
$0.1223
gross reimbursed
vs
NADAC / ea
$0.0339
acquisition cost
=
Spread
+$0.0884
+261% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
51% FFS 49% MCO
Fee-for-service · 17,376 Rx Managed care · 16,486 Rx
State Medicaid map
Alaska: 6,964 units · 950 per 100k residents AK Maine: 35,889 units · 2,573 per 100k residents ME Washington: 53,679 units · 687 per 100k residents WA Idaho: 7,821 units · 398 per 100k residents ID Montana: 6,593 units · 582 per 100k residents MT North Dakota: 2,987 units · 381 per 100k residents ND Minnesota: 28,757 units · 501 per 100k residents MN Wisconsin: 38,722 units · 655 per 100k residents WI Michigan: 86,812 units · 865 per 100k residents MI New York: 266,420 units · 1,361 per 100k residents NY Vermont: 2,908 units · 449 per 100k residents VT New Hampshire: 12,151 units · 867 per 100k residents NH Oregon: 64,441 units · 1,522 per 100k residents OR Nevada: 33,600 units · 1,052 per 100k residents NV Wyoming: 4,037 units · 691 per 100k residents WY South Dakota: 1,453 units · 158 per 100k residents SD Iowa: 12,954 units · 404 per 100k residents IA Illinois: 50,751 units · 404 per 100k residents IL Indiana: 25,864 units · 377 per 100k residents IN Ohio: 55,129 units · 468 per 100k residents OH Pennsylvania: 112,380 units · 867 per 100k residents PA New Jersey: 45,706 units · 492 per 100k residents NJ Massachusetts: 29,071 units · 415 per 100k residents MA California: 1,160,928 units · 2,979 per 100k residents CA Utah: 14,604 units · 427 per 100k residents UT Colorado: 14,558 units · 248 per 100k residents CO Nebraska: 13,476 units · 681 per 100k residents NE Missouri: 29,868 units · 482 per 100k residents MO Kentucky: 63,736 units · 1,408 per 100k residents KY West Virginia: 21,123 units · 1,193 per 100k residents WV Virginia: 65,145 units · 747 per 100k residents VA Maryland: 72,062 units · 1,166 per 100k residents MD Connecticut: 20,318 units · 562 per 100k residents CT Rhode Island: 2,113 units · 193 per 100k residents RI Arizona: 64,469 units · 868 per 100k residents AZ New Mexico: 15,828 units · 749 per 100k residents NM Kansas: 3,527 units · 120 per 100k residents KS Arkansas: 11,247 units · 367 per 100k residents AR Tennessee: 18,219 units · 256 per 100k residents TN North Carolina: 40,067 units · 370 per 100k residents NC South Carolina: 11,346 units · 211 per 100k residents SC Delaware: 2,483 units · 241 per 100k residents DE Oklahoma: 10,982 units · 271 per 100k residents OK Louisiana: 19,390 units · 424 per 100k residents LA Mississippi: 4,942 units · 168 per 100k residents MS Alabama: 6,953 units · 136 per 100k residents AL Georgia: 23,043 units · 209 per 100k residents GA D.C.: 11,010 units · 1,622 per 100k residents DC Hawaii: 5,540 units · 386 per 100k residents HI Texas: 35,181 units · 115 per 100k residents TX Florida: 32,250 units · 143 per 100k residents FL
Units reimbursed · per 100k residents
1152,979
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 California 2,979 /100k
2 Maine 2,573 /100k
3 D.C. 1,622 /100k
4 Oregon 1,522 /100k
5 Kentucky 1,408 /100k
6 New York 1,361 /100k
7 West Virginia 1,193 /100k
8 Maryland 1,166 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets60505-0141-01 130,277 Rx · $1,372,439
500 tablets60505-0141-02 60,108 Rx · $672,640
100 tablets this page60505-0141-00 33,862 Rx · $346,038
18000 tablets60505-0141-08 12 Rx · $166
Drug total (last 4 qtrs): 224,259 Rx · 16,636,939 units · $2,391,282 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Glipizide — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Glipizide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.01M
Claims incl. refills
1.1M
Beneficiaries
795.9K
Spend / beneficiary
$16.34
Spend / claim
$12.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 60505-0134-00 · Apotex 60505-0142-00 · Apotex →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.